- Home
- SNTG vs MYNZ Comparison
SNTG vs MYNZ Comparison
Compare SNTG & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SNTG | MYNZ |
|---|---|---|
| Founded | 2009 | 2021 |
| Country | China | Germany |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNTG | MYNZ |
|---|---|---|
| Price | $2.17 | $1.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 13.5K | ★ 930.5K |
| Earning Date | 04-27-2026 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $107,507.00 | ★ $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.43 | $0.92 |
| 52 Week High | $12.70 | $8.20 |
Technical Indicators
Market Signals| Indicator | SNTG | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.89 | 43.04 |
| Support Level | $2.07 | $1.00 |
| Resistance Level | $2.49 | $1.13 |
| Average True Range (ATR) | 0.16 | 0.13 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 50.00 | 36.36 |
Price Performance
Historical ComparisonAbout SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.